公开(公告)号：US09636418B2

公开(公告)日：2017-05-02

申请号：US14207445

申请日：2014-03-12

Applicant: AMGEN INC.

Inventor： Justin K. Murray ,  Jerry Ryan Holder ,  Malgorzata Wanska ,  Christopher M. Tegley ,  James R. Falsey ,  Elizabeth M. Doherty ,  Leslie P. Miranda

IPC: C07K14/435 ,  A61K47/48 ,  C07K16/44 ,  C07K14/705 ,  A61K38/00

CPC classification number: A61K47/48438 ,  A61K38/00 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6817 ,  C07K14/43518 ,  C07K14/705 ,  C07K16/44

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

公开(公告)号：US11807693B2

公开(公告)日：2023-11-07

申请号：US17160819

申请日：2021-01-28

Applicant: AMGEN INC.

Inventor： Jerry Ryan Holder ,  Gayathri Swaminath ,  Michael J. Frohn ,  Brian Alan Lanman ,  Anthony B. Reed ,  Leslie P. Miranda ,  John Gordon Allen ,  Alexander J. Pickrell ,  Aaron C. Siegmund ,  Lewis D. Pennington ,  Bryant Yang

IPC: C07K7/08 ,  C07K14/47 ,  A61K47/54 ,  A61K47/60 ,  A61K38/10 ,  A61K38/00

CPC classification number: C07K7/08 ,  A61K38/10 ,  A61K47/542 ,  A61K47/60 ,  C07K14/47 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

公开(公告)号：US10905772B2

公开(公告)日：2021-02-02

申请号：US15872841

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： Yuan Cheng ,  Chawita Netirojjanakul ,  Jerry Ryan Holder ,  Bin Wu ,  James R. Falsey ,  Bradley J. Herberich ,  Kelvin Sham ,  Leslie P. Miranda ,  Shu-Chen Lu ,  Murielle M. Veniant-Ellison ,  Shanaka Stanislaus ,  Junming Yie ,  Jing Xu

IPC: A61K47/68 ,  A61K38/26 ,  A61P3/10 ,  C07K16/28 ,  A61K39/395

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US10941182B2

公开(公告)日：2021-03-09

申请号：US15317911

申请日：2015-06-10

Applicant: AMGEN INC.

Inventor： Jerry Ryan Holder ,  Gayathri Swaminath ,  Michael J. Frohn ,  Brian Alan Lanman ,  Anthony B. Reed ,  Leslie P. Miranda ,  John G. Allen ,  Alexander J. Pickrell ,  Aaron C. Siegmund ,  Lewis D. Pennington ,  Bryant Yang

IPC: C07K7/08 ,  A61K38/10 ,  C07K14/47 ,  A61K47/54 ,  A61K47/60 ,  A61K38/00

Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

公开(公告)号：US12214051B2

公开(公告)日：2025-02-04

申请号：US17151045

申请日：2021-01-15

Applicant: Amgen Inc.

Inventor： Yuan Cheng ,  Chawita Netirojjanakul ,  Jerry Ryan Holder ,  Bin Wu ,  James R. Falsey ,  Bradley J. Herberich ,  Kelvin Sham ,  Leslie P. Miranda ,  Shu-Chen Lu ,  Murielle M. Venient-Ellison ,  Shanaka Stanislaus ,  Junming Yie ,  Jing Xu

IPC: A61K47/68 ,  A61K39/395 ,  A61P3/10 ,  C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US10344060B2

公开(公告)日：2019-07-09

申请号：US14773756

申请日：2014-03-12

Applicant: AMGEN INC.

Inventor： Justin K. Murray ,  Jerry Ryan Holder ,  Malgorzata Wanska ,  Christopher M. Tegley ,  James R. Falsey ,  Elizabeth M. Doherty ,  Leslie P. Miranda ,  Kaustav Biswas ,  Bin Wu ,  Kelvin Sham ,  Jason C. Long

IPC: C07K14/00 ,  C07K14/435 ,  C07K16/00 ,  C07K19/00 ,  C07K14/46 ,  C07K14/47 ,  A61K38/00 ,  A61K38/16 ,  A61K38/17 ,  A61K47/64 ,  A61K47/68

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.